Skip to main content
Equibles
ARQT logo

ARQT · Arcutis Biotherapeutics, Inc. · Earnings Call Transcripts & Audio

Track ARQT — free

Use ARQT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARQT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$26.51 +0.08 (+0.30%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.39B
Shares
125.69M
Volume · Sep 30 2.39M Avg daily vol (3M) 2.18M

Arcutis Biotherapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Arcutis Biotherapeutics, Inc. (ARQT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $725,000 −$107.71M '22 Q3 22-11-08 · $2.96M −$72.02M '22 Q4 23-02-28 · $2.78M −$80.10M '23 Q1 23-05-09 · $5.19M −$70.99M '23 Q2 23-08-08 ▲5156.4% $38.11M −$44.77M '23 Q3 23-11-03 ▲356.8% $13.53M −$66.28M '23 Q4 24-02-27 ▲1682.4% $49.57M −$35.38M '24 Q1 24-05-14 ▲494.6% $30.86M −$52.33M '24 Q2 24-08-14 ▲17.4% $44.76M −$41.54M '24 Q3 24-11-06 ▲427.6% $71.36M −$10.79M '24 Q4 25-01-13 ▲32.8% $65.85M −$25.06M '25 Q1 25-05-06 ▲164.1% $81.50M −$15.89M '25 Q2 25-08-06 ▲121.7% $99.22M $7.41M '25 Q3 25-10-28 ▲81.5% $129.50M $17.39M '25 Q4 26-02-25 ▲60.1% $105.40M −$11.29M '26 Q1 26-05-06 LATEST ▲59.3% $129.86M $15.01M '26 Q2 26-08-05
Conference
Investor event
2026-09-16
Arcutis Biotherapeutics, Inc. (ARQT) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
Confident tone Pediatric label expansion Primary care and pediatric sales force Patient access initiatives
Revenue
$129.86M
▲ 59.3% YoY
Diluted EPS
$0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Arcutis Biotherapeutics, Inc. (ARQT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Confident tone Atopic dermatitis pediatric sNDA (3 to 24 months) Pipeline expansion: vitiligo and HS Phase 2 POC ARQ-234 Phase 1 initiation
Revenue
$105.40M
▲ 60.1% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-14
Arcutis Biotherapeutics, Inc. (ARQT) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-02
Arcutis Biotherapeutics, Inc. (ARQT) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-25
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Confident tone FDA label expansions and submissions Infant atopic dermatitis (INTEGUMENT trial) Zareve (topical roflumilast) commercial growth
Revenue
$129.50M*
▲ 81.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2025 Earnings Call Transcript
Confident tone ZORYVE commercial momentum Pipeline and ARQ-234 biologic Life cycle management and label expansions
Revenue
$99.22M
▲ 121.7% YoY
Diluted EPS
$0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript
Confident tone ZORYVE revenue growth and franchise momentum Seasonality and quarterly guidance Conversion from topical steroids
Revenue
$81.50M
▲ 164.1% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript
Confident tone ZORYVE commercial performance and growth Market expansion from topical steroids Upcoming regulatory catalysts and label expansion
Revenue
$65.85M
▲ 32.8% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript
Confident tone ZORYVE product growth and sales momentum Foam vs. cream cannibalization concerns Label expansion and pipeline indications
Revenue
$71.36M*
▲ 427.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
Confident tone Label expansion and pipeline Kowa co-promotion partnership Government payer access (Medicare/Medicaid)
Revenue
$44.76M
▲ 17.4% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript
Confident tone ZORYVE cream (psoriasis) launch ZORYVE foam (seb derm) launch Atopic dermatitis launch
Revenue
$30.86M
▲ 494.6% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript
Confident tone Atopic dermatitis regulatory and pipeline milestone ZORYVE cream psoriasis launch momentum ZORYVE foam seb derm launch
Revenue
$49.57M
▲ 1682.4% YoY
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript
Confident tone ZORYVE foam seborrheic dermatitis launch ZORYVE cream psoriasis launch momentum Payer access and Medicare/Medicaid expansion
Revenue
$13.53M*
▲ 356.8% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-03
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript
Revenue
$38.11M
▲ 5156.4% YoY
Diluted EPS
$-0.73
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript
Revenue
$5.19M
Diluted EPS
$-1.16
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2023 Earnings Call Transcript
Revenue
$2.78M
Diluted EPS
$-1.31
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2022 Earnings Call Transcript
Revenue
$2.96M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2022 Earnings Call Transcript
Revenue
$725,000
Diluted EPS
$-1.89
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts CIK 1787306 CUSIP 03969K108 13F (30d) 8 filings 7 filers Visit website Investor relations